Alextatug

阿莱妥塔单抗

Report date: 2024/12/20 17:34:34

Base Information

Drug NameAlextatug
Drug Alias NameATRC-101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionImmunomodulatorsPolyadenylate-binding protein 1 inhibitors
TargetsPolyadenylate-binding protein 1
Therapy Area/IndicationsSkin MelanomaFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAtreca Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAtreca Inc
Active IndicationsN/A
Inactive IndicationsSkin MelanomaFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[14] 

Other Information

ATC CodeN/A
Related LinksN/A